



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.10.2022 Bulletin 2022/42

(45) Date of publication and mention
of the grant of the patent:
14.09.2022 Bulletin 2022/37

(21) Application number: **16734529.7**

(22) Date of filing: **21.06.2016**

(51) International Patent Classification (IPC):
C07D 209/94 ^(2006.01) **A61K 31/403** ^(2006.01)
A61P 37/00 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 9/00** ^(2006.01)
A61P 1/00 ^(2006.01) **A61P 7/00** ^(2006.01)
A61P 3/00 ^(2006.01) **A61P 5/00** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 209/94; A61P 1/00; A61P 1/04; A61P 1/16;
A61P 3/00; A61P 3/10; A61P 5/00; A61P 7/00;
A61P 9/00; A61P 17/02; A61P 17/06; A61P 17/10;
A61P 19/02; A61P 25/00; A61P 29/00; (Cont.)

(86) International application number:
PCT/US2016/038506

(87) International publication number:
WO 2016/209809 (29.12.2016 Gazette 2016/52)

(54) **CRYSTALLINE L-ARGININE SALT OF
(R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS**

KRISTALLINES L-ARGININSALZ VON (R) -2-(7-(4-CYCLOPENTYL-3-(TRIFLUORMETHYL) BENZYLOXY) -1,2,3,4-TETRAHYDROCYCLO-PENTA [B] INDOL-3-YL) ESSIGSÄURE ZUR VERWENDUNG BEI S1P1-REZEPTOR-ASSOZIERTEN ERKRANKUNGEN

SEL L-ARGININE CRISTALLIN D'ACIDE
(R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMÉTHYL)BENZYLOXY)-1,2,3,4-TÉTRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACÉTIQUE POUR UNE UTILISATION DANS DES TROUBLES ASSOCIÉS AU RÉCEPTEUR DE S1P1

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: **22.06.2015 US 201562182841 P**
20.08.2015 US 201562207531 P

(43) Date of publication of application:
25.04.2018 Bulletin 2018/17

(60) Divisional application:
21178613.2 / 3 939 965

(73) Proprietor: **Arena Pharmaceuticals, Inc.**
New York, NY 10017 (US)

(72) Inventors:
• **BLACKBURN, Anthony C.**
San Diego, California 92128 (US)
• **CASTRO, Ryan O.**
San Diego, California 92129 (US)
• **HADD, Mark A.**
San Diego, California 92126 (US)
• **MA, You-An**
Poway, California 92064 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **MONTALBAN, Antonio Garrido**
San Diego, California 92129 (US)
 - **RUETER, Jaimie Karyn**
San Diego, California 92129 (US)
 - **SELVEY, Lee Alani**
Poway, California 92064 (US)
 - **SHAKYA, Sagar Raj**
San Diego, California 92129 (US)
 - **CARLOS, Marlon**
Chula Vista, California 91913 (US)
- (74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

- (56) References cited:
- WO-A1-2010/011316 WO-A1-2011/094008**
- **NORBERT RASENACK ET AL:** "Crystal habit and tableting behavior", **INTERNATIONAL JOURNAL OF PHARMACEUTICS**, vol. 244, no. 1-2, 1 September 2002 (2002-09-01), pages 45-57, XP055291502, NL ISSN: 0378-5173, DOI: 10.1016/S0378-5173(02)00296-X
- (52) Cooperative Patent Classification (CPC): (Cont.)
A61P 35/00; A61P 37/00; A61P 37/02;
A61P 43/00; C07C 279/14